Search results for "Transporte"

showing 10 items of 743 documents

Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.

2016

11062Background: Human equilibrative nucleoside transporter 1 (hENT1) is the major gemcitabine transporter into cells. Gemcitabine is an active drug in different sarcoma subtypes including leiomyos...

LeiomyosarcomaDrugCancer Researchbiologybusiness.industrymedia_common.quotation_subjectTransporterEquilibrative nucleoside transporter 1medicine.diseaseGemcitabineOncologybiology.proteinCancer researchMedicineAngiosarcomaSarcomabusinessmedicine.drugmedia_commonJournal of Clinical Oncology
researchProduct

L'obra pública com a imatge del progrés. La creació del "mite de les infrastructures" en l'Espanya liberal (1834-1868)

2007

LiberalismoTransformación espacialUNESCO::HISTORIA::Historia por épocas::Historia antiguaPolíticas públicasIngenieros de caminosPercepción del paisajeObras públicas:HISTORIA::Historia por épocas::Historia antigua [UNESCO]Infraestructuras de transporte
researchProduct

Neural and genetic correlates of antidepressant response to sleep deprivation - A functional magnetic resonance imaging study of moral valence decisi…

2007

Context: Total sleep deprivation combined with light therapy causes rapid amelioration of bipolar depression. A polymorphism in the promoter for the serotonin transporter influences both antidepressant response and the structure and function of specific brain areas. Objective: To determine whether antidepressant therapy or the genotype of the serotonin transporter influence the pattern of neural response to a task targeting the depressive biases in information processing (moral valence decision). Design: Before-and-after trial studying the biologic correlates of response to treatment. Setting: University hospital. Patients: Twenty inpatients with bipolar depression. Intervention: Repeated t…

Light therapyMaleBipolar DisorderGenotypemedicine.medical_treatmentDecision MakingMoralsJudgmentArts and Humanities (miscellaneous)medicineHumansBipolar disorderSerotonin transporterCerebral CortexChronotherapyPsychiatric Status Rating ScalesSerotonin Plasma Membrane Transport ProteinsSleep disorderDepressive Disorder MajorPolymorphism GeneticbiologyHamilton Rating Scale for DepressionMiddle AgedPhototherapymedicine.diseaseCombined Modality TherapyMagnetic Resonance ImagingHospitalizationOxygenPsychiatry and Mental healthSleep deprivationMoodTreatment Outcomebiology.proteinAntidepressantSleep DeprivationFemalemedicine.symptomPsychologyPsychomotor PerformanceClinical psychology
researchProduct

Pharmacogenetic Study of ABCB1 and CYP3A5 Genes During the First Year Following Heart Transplantation Regarding Tacrolimus or Cyclosporine Levels

2011

Pharmacogenetics explains part of the interindividual variability in drug responses. Many published works about the effects of single nucleotide polymorphisms (SNPs) on immunosuppressive drug blood levels present contradictory results. We evaluated the SNPs in ABCB1 (glycoprotein P) and CYP3A5 (metabolic enzyme) genes, seeking correlate them with tacrolimus or cyclosporine levels during the first year after heart transplantation. One blood sample was obtained from each of 41 patients: 26 treated with cyclosporine and 15 with tacrolimus. We characterize the SNPs rs1045642, 1128503, 2032582, 2235013, 2235033, 2229109, 3213619, 9282564 in ABCB1 and rs10264272, 776746 in CYP3A5 genes using the …

Linkage disequilibriummedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BGenotypemedicine.medical_treatmentSingle-nucleotide polymorphismBiologyPharmacologyPolymorphism Single NucleotideGastroenterologyLinkage DisequilibriumTacrolimusGene FrequencyInternal medicineGenotypemedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsATP Binding Cassette Transporter Subfamily B Member 1CYP3A5Heart transplantationTransplantationTacrolimusPhenotypeImmunosuppressive drugPharmacogeneticsSpainCyclosporineHeart TransplantationSurgeryDrug MonitoringImmunosuppressive AgentsPharmacogeneticsTransplantation Proceedings
researchProduct

QUALITATIVE RESEARCH IN TRAVEL BEHAVIOR STUDIES

2016

Qualitative methodology is extensively used in a wide range of scientific areas, such as Sociology and Psychology, and it is been used to study individual and household decision making processes. However, in the Transportation Planning and Engineering domain it is still infrequent to find in the travel behavior literature studies using qualitative techniques to explore activity-travel decisions. The aim of this paper is first, to provide an overview of the types of qualitative techniques available and to explore how to correctly implement them. Secondly, to highlight the special characteristics of qualitative methods that make them appropriate to study activity-travel decision processes. Fa…

Literature review050210 logistics & transportationTransportation planningData collectionActivity Travel Decision ProcessesTransport PlanningManagement science05 social sciences0211 other engineering and technologiesFoundation (evidence)021107 urban & regional planning02 engineering and technologyINGENIERÍA DEL TRANSPORTEDomain (software engineering)INGENIERIA E INFRAESTRUCTURA DE LOS TRANSPORTESTravel behaviorQualitative reasoning0502 economics and businessDecision processQualitativeQualitative research
researchProduct

The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm

2017

Liver Cirrhosis0301 basic medicinemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BCholestasisHepatologybusiness.industryABCB4Gastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicineInternal medicineRealmHumansMedicine030211 gastroenterology & hepatologyIn patientbusinessHepatic fibrosisHepatology
researchProduct

TGF-β2 silencing to target biliary-derived liver diseases

2020

ObjectiveTGF-β2 (TGF-β, transforming growth factor beta), the less-investigated sibling of TGF-β1, is deregulated in rodent and human liver diseases. Former data from bile duct ligated and MDR2 knockout (KO) mouse models for human cholestatic liver disease suggested an involvement of TGF-β2 in biliary-derived liver diseases.DesignAs we also found upregulated TGFB2 in liver tissue of patients with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), we now fathomed the positive prospects of targeting TGF-β2 in early stage biliary liver disease using the MDR2-KO mice. Specifically, the influence of TgfB2 silencing on the fibrotic and inflammatory niche was analysed on m…

Liver CirrhosisATP Binding Cassette Transporter Subfamily B2312Cholangitis SclerosingPrimary sclerosing cholangitisMiceTransforming Growth Factor beta2Liver diseasePrimary biliary cirrhosisCholestasisFibrosisDrug DiscoveryTGF beta signaling pathwayHepatic Stellate CellsAnimalsHumansMedicineGene silencingGene Silencing1506TGF-betaddc:610Mice KnockoutHepatologybiologyLiver Cirrhosis Biliarybusiness.industryfibrosisGastroenterologyprimary sclerosing cholangitisTransforming growth factor betaOligonucleotides Antisensemedicine.diseaseUp-Regulationprimary biliary cirrhosisDisease Models AnimalGene Expression RegulationCancer researchbiology.proteincholestasisbusinessGut
researchProduct

The antifibrotic potential of a sustained release formulation of a PDGF beta-receptor targeted rho kinase inhibitor

2019

Rho kinase activity in hepatic stellate cells (HSCs) is associated with activation, transformation and contraction of these cells, leading to extracellular matrix production and portal hypertension in liver cirrhosis. Inhibition of rho kinase activity can reduce these activities, but may also lead to side effects, for instance systemic hypotension. This can be circumvented by liver-specific delivery of a rho kinase inhibitor to effector cells. Therefore, we targeted the rho kinase inhibitor Y27632 to the key pathogenic cells in liver fibrosis, i.e. myofibroblasts including activated HSCs that highly express the PDGF beta-receptor, using the drug carrier pPB-MSA. This carrier consists of mou…

Liver CirrhosisDrug targetingPyridinesPolymeric microspheresPharmaceutical Science02 engineering and technologyPharmacologychemistry.chemical_compoundY-27632FibrosisControlled releaseRho-associated protein kinaseMice Knockout0303 health sciencesDrug Carriersrho-Associated KinasesChemistryCIRRHOTIC RATS021001 nanoscience & nanotechnologyMicrospheresY-27632Drug deliveryFemale0210 nano-technologyDrug carrierATP Binding Cassette Transporter Subfamily BSIGNALING CONTRIBUTESLiver fibrosisBiologicalsHEPATIC STELLATE CELLSCell LineMECHANISMSReceptor Platelet-Derived Growth Factor beta03 medical and health sciencesDELIVERYROCK INHIBITORmedicineAnimalsHumansProtein Kinase Inhibitors030304 developmental biologyProtein deliveryPORTAL PRESSUREmedicine.diseaseAmidesTargeted drug deliveryRho kinase inhibitorDelayed-Action PreparationsHepatic stellate cellVASODILATIONJournal of Controlled Release
researchProduct

Changes in glucose transporter expression and nitric oxide production are associated with liver injury in diabetes

2015

In diabetes mellitus (DM), both hyperglycaemia and hyperlipidaemia can initiate accumulation of fat in the liver, which might be further mediated by inducible nitric oxide synthase. We have studied changes in GLUT1, nitric oxide (NO(·)) concentration and liver damage in two rat DM models. STZ model was induced by strepozotocin 50 mg/kg. HS model was induced by high-fat diet and 30 mg/kg streptozotocin. GLUT1 expression was studied by means of real-time RT-PCR and immunohistochemistry. Production of NO(·) was monitored by means of erythrocyte sedimentation rate spectroscopy of Fe-DETC-NO complex. Liver damage was assessed using histological activity index (HAI). NO(·) concentration was incre…

Liver injurymedicine.medical_specialtybiologyChemistryClinical BiochemistryGlucose transporternutritional and metabolic diseasesCell BiologyGeneral Medicinemedicine.diseasemedicine.disease_causeStreptozotocinBiochemistryNitric oxideNitric oxide synthasechemistry.chemical_compoundEndocrinologyInternal medicinebiology.proteinmedicineGLUT1Oxidative stressGlucose Transporter Type 1medicine.drugCell Biochemistry and Function
researchProduct

Induction of stress resistance and extension of lifespan in Chaenorhabditis elegans serotonin-receptor knockout strains by withanolide A

2021

Abstract Introduction Approximately 300 million people worldwide suffer from depression. The COVID-19 crisis may dramatically increase these numbers. Severe side effects and resistance development limit the use of standard antidepressants. The steroidal lactone withanolide A (WA) from Withania somnifera may be a promising alternative. Caenorhabditis elegans was used as model to explore WA's anti-depressive and anti-stress potential. Methods C. elegans wildtype (N2) and deficient strains (AQ866, DA1814, DA2100, DA2109 and MT9772) were used to assess oxidative, osmotic or heat stress as measured by generation of reactive oxygen species (ROS), determination of lifespan, and mRNA expression of …

LongevityPharmaceutical SciencePharmacologyWithaniamedicine.disease_cause03 medical and health sciencesGene Knockout Techniques0302 clinical medicineFluoxetineDrug DiscoverymedicineAnimalsCaenorhabditis elegansCaenorhabditis elegans ProteinsWithanolidesCaenorhabditis elegansSerotonin transporter5-HT receptor030304 developmental biologyPharmacology0303 health sciencesFluoxetinebiologyPlant ExtractsWild typebiology.organism_classificationMolecular Docking SimulationOxidative StressComplementary and alternative medicine030220 oncology & carcinogenesisReceptors Serotoninbiology.proteinAntidepressantMolecular MedicineSerotoninReactive Oxygen SpeciesOxidative stressmedicine.drugPhytomedicine
researchProduct